Clinical Trials

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

460 enrolled

Gynecologic

Ovarian Cancer Recurrent

NCT07111546 2026-05-26

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

140 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT07214779 2026-05-26

MAESTRA 2

466 enrolled

Gynecologic

Ovarian Neoplasms

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 2 Active not recruiting

376 enrolled

Breast

Breast Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

11 enrolled

Urinary Bladder Neoplasms

NCT05139017 2026-05-22

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

27 enrolled

Resectable Intrahepatic Cholangiocarcinoma

NCT06312137 2026-05-22

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06545955 2026-05-22

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT06841354 2026-05-22

TroFuse-011

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast

Breast Neoplasms

NCT07325539 2026-05-22

LIGHT

Phase 2 Not yet recruiting

55 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07603856 2026-05-22

REVIVE

39 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07604766 2026-05-22

RAINFOL-02

82 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT07598318 2026-05-20

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Phase 2/3 Not yet recruiting

164 enrolled

Phase 2 Not yet recruiting

Cholangiocarcinoma

NCT07599995 2026-05-20

GENE

34 enrolled

Phase 2 Active not recruiting

Biliary Tract Neoplasms

NCT01585805 2026-05-19

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

83 enrolled 23 charts

Pancreatic Neoplasms

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05615818 2026-05-19

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT06029270 2026-05-19

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

61 enrolled

Phase 1/2 Active not recruiting

Metastatic Pancreatic Ductal Adenocarcinoma

NCT07280377 2026-05-19

GOBLET

122 enrolled

Phase 2/3 Active not recruiting

Anal Cancer Metastatic

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

82 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Suspended

43 enrolled

Phase EARLY_PHASE1 Enrolling by invitation

Pancreatic Neoplasms

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT00210041 2026-05-15

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

Phase 2 Completed

50 enrolled

Genital Neoplasms, Male

NCT05173142 2026-05-15

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

Phase 1/2 Completed

190 enrolled

Stomach Neoplasms

NCT06623422 2026-05-15

INTerpath-009

680 enrolled